Lexeo Therapeutics, Inc. Common Stock

Total Valuation

Lexeo Therapeutics, Inc. Common Stock carries a market capitalization of 353.35M, placing it among publicly traded companies globally. Its enterprise value stands at 190.43M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Lexeo Therapeutics, Inc. Common Stock currently has 74.09M shares outstanding.

Valuation Ratios

Financial Position

Lexeo Therapeutics, Inc. Common Stock maintains a current ratio of 14.16, meaning it holds 14.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 3.18, indicating elevated leverage, while an interest coverage ratio of -522.74 demonstrates limited ability to service its debt obligations.

Financial Efficiency

Stock Price Statistics

Lexeo Therapeutics, Inc. Common Stock's stock has gained approximately 59.57447% over the past 52 weeks. The 50-day moving average sits at 5.73, while the 200-day moving average is 7.16.

Income Statement

EBITDA reached -95.66M, while operating income came in at -97.78M.

Balance Sheet

Lexeo Therapeutics, Inc. Common Stock holds 193.04M in cash and equivalents against 7.37M in total debt, resulting in a net debt position of -71.77M. Total book value stands at -400.32M, with working capital of 186.67M providing operational flexibility.

Cash Flow

Lexeo Therapeutics, Inc. Common Stock produced -97.99M in operating cash flow over the past twelve months. After subtracting -432,000.00 in capital expenditures, free cash flow totaled -98.42M - equivalent to -1.50 per share.

Dividends & Yields

Scores

Lexeo Therapeutics, Inc. Common Stock posts an Altman Z-Score of 9.33, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.